Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Auric Goldfinger's Short List -- Ignore unavailable to you. Want to Upgrade?

To: lindend who wrote (3098)	9/15/1999 1:17:00 PM
From: ekn	Respond to of 19428

Watch WAVX for sell on the news play down to single-digits.

To: lindend who wrote (3098)	9/15/1999 1:24:00 PM
From: Sir Auric Goldfinger	Read Replies (1) \| Respond to of 19428

The company has submitted an application for Evacet to be approved as a front-line therapy for metastatic breast cancer. There are three potential outcomes at this meeting. 1. Some type of recommendation (less than first-line therapy) at no better than 50/50. The estimate is that should this occur, LIPO's stock price could trade up from current levels. 2. Outright rejection as a first-line therapy. The estimate is that there is a 80% chance of this occurring and that the stock could trade significantly lower from current levels. 3. Recommendation as first-line therapy. The estimate is that there is a 20% chance of this occurring and that the stock could trade substantially higher from current levels.